Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI as a stroke shield: a 26,000-Person test

NCT ID NCT07779668

Prevention Sponsor: Xuanwu Hospital, Beijing Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Sep 03, 2026 · Updated 2 times

Summary

This trial tests whether an AI-driven health management program can reduce the chance of a first ischemic stroke in adults at high risk. Participants in Beijing communities will be randomly assigned to either AI-supported care or usual community health services. The AI program uses digital tools, wearable data, and personalized guidance to help manage risk factors. Over 36 months, researchers will compare stroke rates between the two groups to see if the AI approach makes a difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI-driven dynamic health management platform (AI-ExpoStroke) with digital tools, wearables, and personalized guidance
What this could lead to
If successful, this could establish AI-supported health management as an effective strategy to prevent first strokes in high-risk populations, potentially reducing stroke-related disability and death.
What could go wrong
The trial is large but relies on community-based implementation, which may vary in adherence. The AI model's predictive accuracy and the intervention's real-world effectiveness are unproven, and results may not generalize beyond Beijing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 26,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 30 years or older, with no restriction on sex. * Permanent resident of Beijing. * No previously diagnosed stroke based on prospective community screening. * Identified as being at high risk of stroke by the AI-ExpoStroke model in combination with the established stroke "8+2" high-risk factors. * Able to comply with study follow-up and willing to provide informed consent. Exclusion Criteria: * Previous diagnosis of ischemic stroke or hemorrhagic stroke. * Severe cognitive impairment. * Severe organic disease, including malignant tumors, New York Heart Association (NYHA) class III or higher heart failure, renal failure, or other severe conditions. * Psychiatric or language impairment that prevents completion of study questionnaires or follow-up. * Inability to obtain complete follow-up data or unwillingness to permit access to relevant study data.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ischemic stroke prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ischemic stroke

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.